File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Advantages of blood pressure optimization

TitleAdvantages of blood pressure optimization
Authors
KeywordsAntihypertensive drugs
Blood pressure
Endothelial function
Hypertension
Left ventricular hypertrophy
Issue Date2005
PublisherSpringer Healthcare Communications Ltd. The Journal's web site is located at http://www.springerhealthcare.com/ait/index.htm
Citation
Advances In Therapy, 2005, v. 22 n. 4, p. 285-296 How to Cite?
AbstractLowering blood pressure (BP) reduces cardiovascular events, but aggressive BP management may not be advantageous. Optimal BP control (target: <120/80 mm Hg) and conventional BP control (target: <140/90 mm Hg) were compared in patients with hypertension in terms of target-organ damage and tolerability. A total of 23 patients with hypertension were randomly assigned to optimal versus conventional therapy for 6 months. Therapy was initiated with lercanidipine 10 mg/day. For BP control, the dose could be doubled or other drugs added. Three indices of target-organ damage were studied: left ventricular mass (LVM) index, flow-mediated dilatation (FMD) of the brachial artery, and 24-hour urinary albumin excretion. The BP decreased markedly by 21.3±3.4/13.2±1.7 mm Hg in the conventional therapy group and by 26.6±3.6/17.9±1.5 mm Hg in the optimal therapy group. Diastolic BP was significantly lower, by 4.7±2.3 mm Hg, in the optimal therapy group (P<.05). Ambulatory BP was also decreased in both groups. There was no significant change in LVM or FMD in either group. Baseline LVM index and FMD values were correlated with systolic BP (r=0.51, P=.02; r=0.54, P=.009). In the optimal therapy group, urinary albumin excretion increased significantly (P=.04). Plasma levels of B-type natriuretic peptide (BNP) decreased with antihypertensive therapy (P=.03). Treatment was well tolerated, and none of the patients withdrew from the study. There was no significant difference in adverse events between the 2 groups. Optimization of BP is feasible, safe, and well tolerated; however, a larger study of longer duration may be needed to demonstrate improvements in LVM and endothelial function with conventional versus optimal therapy. ©2005 Health Communications Inc.
Persistent Identifierhttp://hdl.handle.net/10722/78283
ISSN
2015 Impact Factor: 2.503
2015 SCImago Journal Rankings: 0.790
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, BMYen_HK
dc.contributor.authorMan, YBen_HK
dc.contributor.authorTse, HFen_HK
dc.contributor.authorKumana, CRen_HK
dc.contributor.authorLau, CPen_HK
dc.date.accessioned2010-09-06T07:41:10Z-
dc.date.available2010-09-06T07:41:10Z-
dc.date.issued2005en_HK
dc.identifier.citationAdvances In Therapy, 2005, v. 22 n. 4, p. 285-296en_HK
dc.identifier.issn0741-238Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/78283-
dc.description.abstractLowering blood pressure (BP) reduces cardiovascular events, but aggressive BP management may not be advantageous. Optimal BP control (target: <120/80 mm Hg) and conventional BP control (target: <140/90 mm Hg) were compared in patients with hypertension in terms of target-organ damage and tolerability. A total of 23 patients with hypertension were randomly assigned to optimal versus conventional therapy for 6 months. Therapy was initiated with lercanidipine 10 mg/day. For BP control, the dose could be doubled or other drugs added. Three indices of target-organ damage were studied: left ventricular mass (LVM) index, flow-mediated dilatation (FMD) of the brachial artery, and 24-hour urinary albumin excretion. The BP decreased markedly by 21.3±3.4/13.2±1.7 mm Hg in the conventional therapy group and by 26.6±3.6/17.9±1.5 mm Hg in the optimal therapy group. Diastolic BP was significantly lower, by 4.7±2.3 mm Hg, in the optimal therapy group (P<.05). Ambulatory BP was also decreased in both groups. There was no significant change in LVM or FMD in either group. Baseline LVM index and FMD values were correlated with systolic BP (r=0.51, P=.02; r=0.54, P=.009). In the optimal therapy group, urinary albumin excretion increased significantly (P=.04). Plasma levels of B-type natriuretic peptide (BNP) decreased with antihypertensive therapy (P=.03). Treatment was well tolerated, and none of the patients withdrew from the study. There was no significant difference in adverse events between the 2 groups. Optimization of BP is feasible, safe, and well tolerated; however, a larger study of longer duration may be needed to demonstrate improvements in LVM and endothelial function with conventional versus optimal therapy. ©2005 Health Communications Inc.en_HK
dc.languageengen_HK
dc.publisherSpringer Healthcare Communications Ltd. The Journal's web site is located at http://www.springerhealthcare.com/ait/index.htmen_HK
dc.relation.ispartofAdvances in Therapyen_HK
dc.subjectAntihypertensive drugsen_HK
dc.subjectBlood pressureen_HK
dc.subjectEndothelial functionen_HK
dc.subjectHypertensionen_HK
dc.subjectLeft ventricular hypertrophyen_HK
dc.subject.meshAntihypertensive Agents - therapeutic use-
dc.subject.meshHypertension - drug therapy - physiopathology-
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.titleAdvantages of blood pressure optimizationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1936-0851&volume=22&issue=4&spage=285&epage=96&date=2005&atitle=Advantages+of+blood+pressure+optimizationen_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid16418138-
dc.identifier.scopuseid_2-s2.0-29344446140en_HK
dc.identifier.hkuros114950en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-29344446140&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume22en_HK
dc.identifier.issue4en_HK
dc.identifier.spage285en_HK
dc.identifier.epage296en_HK
dc.identifier.isiWOS:000234118200001-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK
dc.identifier.scopusauthoridMan, YB=10245005900en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.scopusauthoridKumana, CR=7005112381en_HK
dc.identifier.scopusauthoridLau, CP=7401968501en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats